A published case series reports unexpected cancer remissions linked with fenbendazole use, prompting renewed discussion on ...

PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec. 23, ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to ...

Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks ...

An update from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) is now available. Clarity Pharmaceuticals announced that data from its Phase II Co-PSMA ...

Treatments for localised prostate cancer have long been aimed at treating the whole prostate, either by surgical removal or by radiotherapy. However ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 ...

Management believes that these results support a near-term new drug application submission in China, which it has described ...

Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule oncology approaches with immunotherapeutic effects, today announced that the pre-specified efficacy ...

The MCED test shows similar performance in cancer survivors and the general population, with a PPV of 50% and high ...